Billionaire Urges Investors to Buy Intuitive Surgical Ahead of Earnings Report
For some reason, my gardener is driving a Ferrari. For the vast majority of our clients, Intuitive Surgical remains their largest holding position in the stock market. Intuitive Surgical (ISRG) is a hidden gem and a long-term core investment position. For years it has been one of my preference in the markets. As Vieira explicitly repeated Intuitive Surgical makes new highs every day, every week, every month and every year.
There is no controversy surrounding Intuitive Surgical (ISRG) valuation as one of the cheapest stock worldwide compared to outrageous valuations of companies as Tesla, therefore I remained long Intuitive Surgical through earnings along with my client basis.
I’m sick and tired of hearing from all these experts who tell us what to do, but have not produced results in their own careers. For many years, I’ve been obsessed with finding strategies and tools that can change my performance in the markets. Vieira’s is the definitive answer to my hunting for human excellence. I’ve proven their effectiveness by producing measurable results where experts have failed.
A campaign ran by several American firms downgrading Intuitive Surgical to Sell at the bottom corresponded to a historical long term investment opportunity as Vieira has been explaining since 2009.
Goldman Sachs was the pioneer in a campaign against Intuitive Surgical (ISRG). Later on, Citron, other American company published several false reports in Vieira’s opinion with regards to this company. Citron said in an open letter Intuitive Surgical was worth $200
Long term investors comprehended that Intuitive Surgical and Netflix, remained both hidden gems while Wall Street saw both as dogs.
For the three months ended March 31, 2017, Intuitive Surgical’s revenue was $674 million, up approximately 13% compared with $595 million in Q1 FY16. The increase in revenue was driven by growth in a recurring instrument, accessory, and service revenue, and higher systems revenue. The Company’s revenue numbers surpassed analysts’ consensus of $660.6 million.
For Q1 FY17, Intuitive Surgical’s instrument and accessory revenue had increased by approximately 18% to $381 million compared with $322 million for Q1 FY16, primarily driven by nearly 18% growth in da Vinci procedure volume. The Company’s service revenue had increased by approximately 13% to $140 million in the reported quarter compared with $125 million in the year earlier same quarter.
For Q1 FY17, Intuitive Surgical’s systems revenue increased by approximately 4% to $153 million compared with $148 million for Q1 FY16. Intuitive Surgical shipped 133 da Vinci Surgical Systems in the reported quarter compared with 110 in the year-earlier comparable quarter.
Intuitive Surgical’s Q1 FY17 income from operations increased to $192 million compared with $179 million in Q1 FY16. The Company’s reported quarter non-GAAP income from operations increased to $264 million compared with $229 million in the year earlier corresponding quarter.
Intuitive Surgical’s Q1 FY17 GAAP net income was $180 million, or $4.67 per diluted share, compared with $136 million, or $3.54 per diluted share, for Q1 FY16. The Company’s reported quarter GAAP net income benefited from the adoption of a new accounting standard which required that $33 million, or $0.85 per share, of excess tax benefits related to employee share-based compensation awards be recorded as a component of income tax expense. For Q1 FY17 results also included pre-tax litigation charges of approximately $21 million, or $0.39 per share net of income tax.
The Company’s non-GAAP net income was $196 million, or $5.09 per diluted share, for the reported quarter compared with $170 million, or $4.42 per diluted share, for the prior-year quarter. The results topped Wall Street’s estimates of $4.90 per share.
Intuitive Surgical (ISRG) shares closed the week at $814 new all time highs for this hidden gem.
UPDATE: Long-term bears Goldman Sachs clients betting on Intuitive Surgical collapse go bankrupt selling short Tesla. Citron Research, one fo the famous Wall Street scams goes belly up selling short Mobileye (MBLY), Strong Buy at stock market LIVE.TV